Event Brief
Apr 27, 2026 at 8:00 AM ET
Intellia says Crispr therapy met Phase 3 goals
By The BriefBrief
Intellia Therapeutics said its Crispr treatment for hereditary angioedema met its goals in a Phase 3 trial.
WHO: Intellia Therapeutics
WHAT: said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial
WHEN: Apr 27, 2026 at 7:01 AM ET
WHERE: Location not specified
WHY: Part of a scheduled clinical trial process.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 21462 of 21461
Same format. Every time.
Continue reading — sign in or create a free account with
